Related Experiment Video
Updated: Aug 20, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Clinical perspective on desmoplastic small round-cell tumor
Alberto Gil1, Alberto Gomez Portilla, Erwin A Brun
1Washington Cancer Institute, Washington, DC 20010, USA.
Abstract:
Rare diseases are often associated with uninformed medical decisions and poorly executed treatments because of inexperience of the physicians. Desmoplastic small round-cell tumor is a rare disease that is a form of peritoneal surface malignancy usually affecting young males, with a mean survival of 29 months. In order to begin to build a more knowledgeable clinical pathway all 7 patients treated at the Washington Hospital Center were studied and compared to patients described in the medical literature. Clinical and pathological data, tumor distribution, cytoreductive surgery, completeness of cytoreduction and survival were recorded and analyzed. The first most common symptoms were pain, increased abdominal girth and palpable abdominal mass in our patients and in the literature review. The overall survival did not improve with cytoreductive surgery plus intraperitoneal chemotherapy (mean survival 32 months); however, 2 long-term survivors who responded to systemic chemotherapy of 55 and 101 months were recorded. The latter may be the longest survivor reported in the literature. No consistent response to chemotherapy was observed in our patients or in any literature review. Complete surgical removal of this malignancy did not correlate with survival in our patients. The absence of improved survival of our aggressively treated patients as compared to the literature was thought to be a consequence of an advanced stage of the disease. A new comprehensive approach that uses complete clearing of cancer by surgery and perioperative systemic and perioperative intraperitoneal chemotherapy as early as is possible in the natural history of the disease emerged as goals for future management.
Insights
Desmoplastic small round-cell tumor (DSRCT) is a rare cancer. Aggressive treatment did not improve survival, but early intervention with surgery and chemotherapy may offer future hope.
Area of Science:
- Oncology
- Rare Cancers
- Peritoneal Surface Malignancy
Background:
- Desmoplastic small round-cell tumor (DSRCT) is a rare, aggressive malignancy primarily affecting young males.
- Characterized by peritoneal surface involvement and a historically poor prognosis with a mean survival of 29 months.
Purpose of the Study:
- To analyze clinical and pathological data of DSRCT patients treated at a single institution.
- To compare outcomes with existing literature data to inform clinical pathway development.
- To evaluate the efficacy of cytoreductive surgery and intraperitoneal chemotherapy.
Main Methods:
- Retrospective analysis of 7 DSRCT patients treated at Washington Hospital Center.
- Comparison with a comprehensive review of DSRCT cases from medical literature.
- Data collection included clinical presentation, tumor distribution, surgical intervention, and survival outcomes.
Main Results:
- Common symptoms include abdominal pain, increased girth, and palpable mass.
- Cytoreductive surgery plus intraperitoneal chemotherapy showed a mean survival of 32 months, not improving upon historical data.
- Two long-term survivors (55 and 101 months) achieved response with systemic chemotherapy; complete surgical removal did not correlate with survival.
Conclusions:
- Aggressive treatment strategies did not significantly improve overall survival, likely due to advanced disease stage at diagnosis.
- Complete surgical resection alone did not correlate with improved survival.
- A comprehensive approach involving early, complete surgical tumor clearing combined with perioperative systemic and intraperitoneal chemotherapy is proposed for future management.
